Table 5.

Myocarditis and pericarditis adverse events reported following Moderna or Pfizer/BioNTech mRNA vaccination stratified by immunocompromised subgroups

Immunocompromised characteristic	EudraVigilance		VAERS		Total
									Pfizer/BioNTech	Moderna	Pfizer/BioNTech	Moderna	Pfizer/BioNTech		Moderna
	N	% (95% CI)	N	% (95% CI)
	Transplant	20	4	7	2	27	24.77 (17.00 to 33.96)	6	20.69 (7.99 to 39.72)
Methotrexate-treated patients	12	2	1	8	13	11.93 (6.51 to 19.53)	10	34.48 (17.94 to 54.33)
HIV	2	0	4	3	6	5.5 (2.05 to 11.60)	3	10.34 (2.19 to 27.35)
Cancer therapeutics	41	1	22	9	63	57.8 (47.96 to 67.20)	10	34.48 (17.94 to 54.33)
Total	75	7	34	22	109	100	29	100

Reports of myocarditis, pericarditis or myopericarditis were searched in the EudraVigilance and VAERS database following COVID-19 mRNA vaccines, either Moderna or Pfizer/BioNTech. The resultant reports were further assessed for individuals that were likely to be immunocompromised based on the following search terms (transplant, immunosuppressant drugs; tacrolimus, mycophenolate mofetil, methotrexate, prednisolone, ciclosporin and steroids, HIV or approved cancer therapeutics: https://www.cancer.gov/about-cancer/treatment/drugs). Values indicate the events reported from each vaccine manufacture within each immunocompromised category. Percentage of the total reports for each manufacture are calculated for each of the characteristic categories.

mRNA, messenger RNA; VAERS, Vaccine Adverse Event Reporting System.